



9-23-04

1651

Express Mail No.: EV 544892818 US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Dingivan *et al.*

Confirmation No.: 7180

Application No.: 10/091,236

Group Art Unit: 1651

Filed: March 4, 2002

Examiner: To Be Assigned

For: METHODS OF PREVENTING OR  
TREATING INFLAMMATORY OR  
AUTOIMMUNE DISORDERS BY  
ADMINISTERING INTEGRIN  
ALPHANUBETA3 ANTAGONISTS  
IN COMBINATION WITH OTHER  
PROPHYLACTIC OR  
THERAPEUTIC AGENTS

Attorney Docket No.: 10271-053-999

**INFORMATION DISCLOSURE**  
**STATEMENT UNDER 37 C.F.R. §1.56 AND §1.97**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

~~In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and~~  
§ 1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby invite the Examiner's attention to the references **A01** to **A70** listed on the attached revised form PTO 1449 entitled "List of References Cited by Applicant." Copies of references **A01** to **A70** are submitted herewith.

Identification of the listed references is not meant to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application. While not to be construed as indicating that the Examiner should not review and consider fully all of the references, Attorneys for Applicants particularly direct the Examiner's attention to references: A01-A08, A10-A12, A14-A16, A19-A21, A23, A26, A28, A29, A32-A38, A41-A51, A53, A55, A56, A58 and A60-A67.


Pursuant to 37 C.F.R. § 1.97(b)(3), Applicants estimate that no fee is due in connection with the filing of this Information Disclosure Statement. However, should the Patent Office determine otherwise, please charge the necessary fee to Jones Day Deposit Account No. 50-3013. A duplicate of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date September 22, 2004

	<u>Margaret B. Brivanlou</u>	40,922
	Margaret B. Brivanlou	(Reg. No.)
By:	<u>Jennifer J. Chheda</u>	46,617
	Jennifer J. Chheda	(Reg. No.)
	ONES DAY	
	222 East 41 <sup>st</sup> Street	
	New York, New York 10017-6702	
	(212) 326-3939	

Enclosures



## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10271-053-999

APPLICATION NO.

10/091,236

APPLICANT

Dingivan and Wilder

FILING DATE


March 4, 2002

GROUP


1651

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	60/316,321		Wilder			8/31/01
	A02	09/339,222		Huse and Wu			6/24/99
	A03	09/081,522		Huse			5/19/98
	A04	2001/0011125	8/2/01	Huse, W.			
	A05	6,596,850	7/22/03	Huse			
	A06	6,590,079	7/8/03	Huse			
	A07	6,171,787	1/9/01	Wiley			
	A08	6,171,588	1/9/01	Carron et al.			
	A09	6,162,432	12/19/00	Wallner et al			
	A10	6,160,099	12/12/00	Jonak et al.			
	A11	6,153,628	11/28/00	Jin et al.			
	A12	6,130,231	10/10/00	Wityak et al.			
	A13	6,114,517	9/5/00	Monia et al.			
	A14	6,096,707	8/1/00	Heino et al.			
	A15	6,090,944	7/18/00	Hutchinson			
	A16	6,048,861	4/11/00	Askew et al.			
	A17	6,036,978	3/14/00	Gombotz et al.			
	A18	5,994,510	11/30/99	Adair et al.			
	A19	5,985,278	11/16/99	Mitjans et al.			
	A20	5,968,741	10/19/99	Plevy et al.			
	A21	5,959,087	9/28/99	Rathjen et al.			
	A22	5,958,412	9/28/99	Welt et al.			
	A23	5,955,572	9/21/99	Ruoslahti et al.			
	A24	5,951,983	9/14/99	Bazin et al.			
	A25	5,928,643	7/27/99	Wallner et al.			
	A26	5,919,452	7/6/99	Le et al.			
	A27	5,914,111	6/22/99	Wallner et al.			
	A28	5,849,692	12/15/98	Jonczyk et al.			



A29	5,830,678	11/3/98	Carter			
A30	5,817,457	10/6/98	Bird et al.			
A31	5,817,311	10/6/98	Bazin et al.			
A32	5,808,029	9/15/98	Brockhaus et al.			
A33	5,780,426	7/14/98	Palladino et al.			
A34	5,770,565	6/23/98	Cheng et al.			
A35	5,767,071	6/16/98	Palladino et al.			
A36	5,753,230	5/19/98	Brooks et al.			
A37	5,741,488	4/21/98	Feldman et al.			
A38	5,736,138	4/7/98	Pfizenmaier et al.			
A39	5,730,979	3/24/98	Bazin et al.			
A40	5,728,677	3/17/98	Wallner et al.			
A41	5,705,481	1/6/98	Jonczyk et al.			
A42	5,698,195	12/16/97	Le et al.			
A43	5,693,612	12/2/97	Jonczyk et al.			
A44	5,658,746	8/19/97	Coan et al.			
A45	5,656,272	8/12/97	Le et al.			
A46	5,652,110	7/29/97	Kim et al.			
A47	5,652,109	7/29/97	Kim et al.			
A48	5,644,034	7/1/97	Rathjen et al.			
A49	5,610,279	3/11/97	Brockhaus et al.			
A50	5,589,570	12/31/96	Tamura et al.			
A51	5,578,704	11/26/96	Kim et al.			
A52	5,547,853	8/20/96	Wallner et al.			
A53	5,523,209	6/4/96	Ginsberg et al.			
A54	5,498,694	3/12/96	Ruoslahti			
A55	5,478,725	12/12/95	Lessey			
A56	5,436,154	7/25/95	Barbanti et al.			
A57	5,426,181	6/20/95	Lee et al.			
A58	5,360,716	11/1/94	Ohmoto et al.			
A59	5,334,380	8/2/94	Kilbourn et al.			
A60	5,306,620	4/26/94	Ginsberg et al.			
A61	5,262,520	11/16/93	Plow et al.			
A62	5,231,024	7/27/93	Moeller et al.			
A63	5,223,395	6/29/93	Gero			
A64	5,204,445	4/20/93	Plow et al.			



A65	5,196,511	3/23/93	Plow et al.			
A66	5,149,780	9/22/92	Plow et al.			
A67	5,147,638	9/15/92	Esmon et al.			
A68	5,136,021	8/4/92	Dembinski et al.			
A69	5,017,691	5/21/91	Lee et al.			
A70	4,658,019	4/14/87	Kung et al.			

### FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO

### OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with **MPEP 609**; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.